Biofilm Formation and Effect of Caspofungin on Biofilm Structure of Candida Species Bloodstream Isolates
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Candida biofilms are microbial communities, embedded in a polymeric matrix, growing attached to a surface, and are highly recalcitrant to antimicrobial therapy. These biofilms exhibit enhanced resistance against most antifungal agents except echinocandins and lipid formulations of amphotericin B. In this study, biofilm formation by different Candida species, particularly Candida albicans , C. tropicalis , and C. parapsilosis , was evaluated, and the effect of caspofungin (CAS) was assessed using a clinically relevant in vitro model system. CAS displayed in vitro activity against C. albicans and C. tropicalis cells within biofilms. Biofilm formation was evaluated after 48 h of antifungal drug exposure, and the effects of CAS on preformed Candida species biofilms were visualized using scanning electron microscopy (SEM). Several species-specific differences in the cellular morphologies associated with biofilms were observed. Our results confirmed the presence of paradoxical growth (PG) in C. albicans and C. tropicalis biofilms in the presence of high CAS concentrations. These findings were also confirmed by SEM analysis and were associated with the metabolic activity obtained by biofilm susceptibility testing. Importantly, these results suggest that the presence of atypical, enlarged, conical cells could be associated with PG and with tolerant cells in Candida species biofilm populations. The clinical implications of these findings are still unknown.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“Candida species are opportunistic pathogens that cause superficial and systemic diseases in critically ill patients (8, 22, 44) and are associated with high mortality rates (35%) and costly treatments (8, 19).”
BackgroundPersister cells, dormancy and infectious disease
Lewis, K. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1557 · Cited by 2,052 · cited 1×
“Persisters were originally described as dormant, slowly growing, or nongrowing cells (26, 35) but are now recognized as drug-tolerant cells that neither grow nor die in the presence of microbicidal antibiotics.”
BackgroundNosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
Candida Infections of Medical Devices
Kojic, E. M., & Darouiche, R. O. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.255-267.2004 · Cited by 1,055
Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989.
Banerjee, S. N., Emori, T. G., Culver, D. H., Gaynes, R. P., Jarvis, W. R., Horan, T., Edwards, J. R., Tolson, J., Henderson, T., Martone, W. J., et al. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90349-3 · Cited by 880 · cited 1×
“hospitals, surpassing gram-negative rods in incidence (6, 17).”
BackgroundCandida albicans Biofilms Produce Antifungal-Tolerant Persister Cells
LaFleur, M. D., Kumamoto, C. A., & Lewis, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00684-06 · Cited by 521 · cited 13×
“ously described the presence of persister cells after exposure to various antifungal drugs (29, 34).”
BackgroundInfluentialMukherjee, P. K., Chandra, J., Kuhn, D. M., & Ghannoum, M. A. (2003) · Infection and Immunity · doi:10.1128/iai.71.8.4333-4340.2003 · Cited by 511 · cited 1×
“In recent years, the ability of Candida species to form biofilms has been evaluated (16, 20, 23, 29, 39, 45, 49, 52).”
BackgroundRamage, G. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf049 · Cited by 468 · cited 1×
“Possible mechanisms include a decreased growth rate; nutrient limitation of cells in the biofilm; expression of resistance genes, particularly those encoding efflux pumps; increased cell density; cell aging; or the presence of “persister” cells in the biofilm (1, 3, 5, 29, 34, 36, 38, 43, 46, 48, 50, 51).”
BackgroundPutative Role of β-1,3 Glucans in Candida albicans Biofilm Resistance
Nett, J., Lincoln, L., Marchillo, K., Massey, R., Holoyda, K., Hoff, B., VanHandel, M., & Andes, D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01056-06 · Cited by 407 · cited 1×
“albicans biofilm cell walls contain significantly higher concentrations of -1,3-glucan than their planktonic counterparts, and these glucans can be found in the supernatant surrounding the biofilm and in the matrix (41).”
BackgroundBiofilm lifestyle of Candida: a mini review
Seneviratne, C., Jin, L., & Samaranayake, L. (2008) · Oral Diseases · doi:10.1111/j.1601-0825.2007.01424.x · Cited by 317
Role of dimorphism in the development of Candida albicans biofilms
BAILLIE, G. S., & DOUGLAS, L. J. (1999) · Journal of Medical Microbiology · doi:10.1099/00222615-48-7-671 · Cited by 304 · cited 2×
“Biofilm cells are characterized by significantly enhanced resistance to some antifungal agents and altered phenotypes, making eradication difficult (4, 11, 31, 32, 48).”
BackgroundEchinocandins: a new class of antifungal
Denning, D. W. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf045 · Cited by 300 · cited 1×
“CAS belongs to the echinocandin family and represents the newest class of antifungal drugs that inhibit the synthesis of -1,3-glucan, a fundamental component of the fungal cell wall, by the inhibition of -1,3-glucan synthase, an enzyme complex that forms glucan polymers in the cell wall (13, 18, 25).”
BackgroundIn Vitro Activity of Caspofungin against Candida albicans Biofilms
Bachmann, S. P., VandeWalle, K., Ramage, G., Patterson, T. F., Wickes, B. L., Graybill, J. R., & López-Ribot, J. L. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3591-3596.2002 · Cited by 288
Effect of Growth Rate on Resistance of Candida albicans Biofilms to Antifungal Agents
Baillie, G. S., & Douglas, L. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.8.1900 · Cited by 234 · cited 1×
“Possible mechanisms include a decreased growth rate; nutrient limitation of cells in the biofilm; expression of resistance genes, particularly those encoding efflux pumps; increased cell density; cell aging; or the presence of “persister” cells in the biofilm (1, 3, 5, 29, 34, 36, 38, 43, 46, 48, 50, 51).”
BackgroundStevens, D. A., Ichinomiya, M., Koshi, Y., & Horiuchi, H. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00563-06 · Cited by 193 · cited 3×
“There are four plausible explanations for this finding: (i) there is an abundance of biofilm production, and such cells may be shifting their metabolism away from regular functions (54, 56); (ii) the biofilm consists of a heterogeneous population with different growth rates, and therefore a subpopulation of cells coul…”
BackgroundRole for Cell Density in Antifungal Drug Resistance in Candida albicans Biofilms
Perumal, P., Mekala, S., & Chaffin, W. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01237-06 · Cited by 165
Adherence of Candida albicans to Silicone Induces Immediate Enhanced Tolerance to Fluconazole
Mateus, C., Crow, S. A., & Ahearn, D. G. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3358-3366.2004 · Cited by 113 · cited 1×
“Possible mechanisms include a decreased growth rate; nutrient limitation of cells in the biofilm; expression of resistance genes, particularly those encoding efflux pumps; increased cell density; cell aging; or the presence of “persister” cells in the biofilm (1, 3, 5, 29, 34, 36, 38, 43, 46, 48, 50, 51).”
BackgroundCateau, E., Rodier, M.-H., & Imbert, C. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn160 · Cited by 98
Cited by
Mechanisms of echinocandin antifungal drug resistance
Perlin, D. S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12831 · Cited by 313
Current Perspectives on Echinocandin Class Drugs
Perlin, D. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.19 · Cited by 274
“However, it is not clear whether transport into the cell is required for echinocandin action, which may explain why the drugs are not subject to the action of multidrug resistant transporters prominent in azole-resistant strains and biofilms [24,25,66].”
BackgroundFungal echinocandin resistance
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267
Martins, M., Henriques, M., Lopez‐Ribot, J. L., & Oliveira, R. (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02047.x · Cited by 174
Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management
Perlin, D. S. (2014) · Drugs · doi:10.1007/s40265-014-0286-5 · Cited by 99
“krusei [13–15], as well as some Candida biofilms [16–19].”
Metadata
- Authors
- Ferreira, J. A. G., Carr, J. H., Starling, C. E. F., de Resende, M. A., & Donlan, R. M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-10
- Volume
- 53
- Issue
- 10
- Pages
- 4377-4384
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2148453289
- Cited by
- 84
- References
- 19
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.